

Supplementary Table S5. Statistical values and distribution of drug-induced papilledema.

Drug	Classification	n	ROR(95%CI)	PRR(X2)	MGPS(95%CI Lower)	BCPNN(95%CI Lower)	p value
Somatotropin	Systemic hormonal preparations	151	22.23(18.8-26.28)	22.18(2776.72)	20.26(17.61)	4.34(2.67)	p<0.001
Mecasermin	Systemic hormonal preparations	4	43.91(16.42-117.42)	43.69(166.47)	43.59(19.14)	5.45(3.78)	p<0.001
Dexamethasone	Systemic hormonal preparations	4	15.99(5.99-42.69)	15.96(55.97)	15.92(7)	3.99(2.32)	p<0.001
Brolucizumab	Sensory organs	22	28.8(18.9-43.89)	28.71(580.61)	28.34(19.92)	4.82(3.16)	p<0.001
Latanoprost	Sensory organs	4	8.02(3.01-21.42)	8.02(24.52)	8(3.52)	3(1.33)	p<0.001
Tezacaftor	Respiratory system	25	15(10.1-22.27)	14.98(321.21)	14.77(10.61)	3.88(2.22)	p<0.001
Fluticasone propionate	Respiratory system	4	12.37(4.63-33.02)	12.35(41.64)	12.33(5.42)	3.62(1.96)	p<0.001
Salmeterol	Respiratory system	3	6.82(2.2-21.18)	6.82(14.87)	6.81(2.64)	2.77(1.1)	p<0.005
Laronidase	Other Medication	3	9.65(3.11-29.98)	9.64(23.2)	9.63(3.73)	3.27(1.6)	p<0.001
Nusinersen	Other Medication	3	6.57(2.12-20.4)	6.57(14.13)	6.56(2.54)	2.71(1.04)	p<0.005
Methylphenidate	Nervous system	9	7.18(3.73-13.84)	7.18(47.61)	7.15(4.13)	2.84(1.17)	p<0.001
Topiramate	Nervous system	5	5.1(2.12-12.28)	5.1(16.43)	5.09(2.44)	2.35(0.68)	p<0.001
Escitalopram	Nervous system	4	6.41(2.4-17.09)	6.4(18.19)	6.39(2.81)	2.68(1.01)	p<0.001
Sevoflurane	Nervous system	3	7.23(2.33-22.46)	7.23(16.07)	7.21(2.8)	2.85(1.18)	p<0.005
Levonorgestrel	Genito urinary system and sex hormones	63	4.66(3.63-6)	4.66(174.36)	4.52(3.66)	2.18(0.51)	p<0.001
Testosterone	Genito urinary system and sex hormones	23	25.13(16.64-37.95)	25.06(524.1)	24.73(17.52)	4.63(2.96)	p<0.001
Sildenafil	Genito urinary system and sex hormones	23	14.57(9.65-22)	14.55(286.27)	14.36(10.18)	3.84(2.18)	p<0.001
Tadalafil	Genito urinary system and sex hormones	7	12.87(6.12-27.05)	12.85(76.19)	12.8(6.88)	3.68(2.01)	p<0.001
Drospirenone	Genito urinary system and sex hormones	7	10.27(4.89-21.58)	10.26(58.25)	10.22(5.49)	3.35(1.69)	p<0.001
Testosterone cypionate	Genito urinary system and sex hormones	6	32.76(14.67-73.14)	32.64(183.38)	32.53(16.61)	5.02(3.35)	p<0.001
Medroxyprogesterone acetate	Genito urinary system and sex hormones	3	57.3(18.39-178.52)	56.93(164.57)	56.83(21.96)	5.83(4.16)	p<0.001
Isotretinoin	Dermatologicals	22	6.44(4.23-9.81)	6.43(99.66)	6.36(4.47)	2.67(1)	p<0.001

Amiodarone	Cardiovascular system	13	14.47(8.38-24.98)	14.45(161.46)	14.34(9.08)	3.84(2.17)	p<0.001
Telmisartan	Cardiovascular system	3	6.3(2.03-19.57)	6.3(13.35)	6.29(2.44)	2.65(0.99)	p<0.005
Tacrolimus	Antineoplastic and immunomodulating agents	34	4.54(3.23-6.37)	4.53(91.73)	4.46(3.36)	2.16(0.49)	p<0.001
Oxaliplatin	Antineoplastic and immunomodulating agents	20	4.27(2.75-6.63)	4.27(49.41)	4.23(2.92)	2.08(0.41)	p<0.001
Bortezomib	Antineoplastic and immunomodulating agents	12	3.88(2.2-6.86)	3.88(25.51)	3.86(2.4)	1.95(0.28)	p<0.001
Interferon alfa-2b	Antineoplastic and immunomodulating agents	12	6.18(3.5-10.91)	6.18(51.71)	6.14(3.82)	2.62(0.95)	p<0.001
Anastrozole	Antineoplastic and immunomodulating agents	11	8.26(4.56-14.95)	8.25(69.67)	8.21(5)	3.04(1.37)	p<0.001
Cytarabine	Antineoplastic and immunomodulating agents	8	62.69(31.22-125.88)	62.25(479.86)	61.95(34.57)	5.95(4.28)	p<0.001
Fulvestrant	Antineoplastic and immunomodulating agents	5	11.35(4.72-27.32)	11.34(46.99)	11.31(5.42)	3.5(1.83)	p<0.001
Letrozole	Antineoplastic and immunomodulating agents	5	6.77(2.82-16.3)	6.77(24.52)	6.75(3.24)	2.76(1.09)	p<0.001
Canakinumab	Antineoplastic and immunomodulating agents	5	5.28(2.19-12.7)	5.28(17.28)	5.26(2.52)	2.4(0.73)	p<0.001
Rituximab	Antineoplastic and immunomodulating agents	4	28.89(10.81-77.2)	28.8(107.09)	28.73(12.62)	4.84(3.18)	p<0.001
Adalimumab	Antineoplastic and immunomodulating agents	4	26.97(10.1-72.07)	26.89(99.49)	26.83(11.79)	4.75(3.08)	p<0.001
Cobimetinib	Antineoplastic and immunomodulating agents	4	11.4(4.27-30.44)	11.39(37.82)	11.36(5)	3.51(1.84)	p<0.001
Sirolimus	Antineoplastic and immunomodulating agents	4	5.6(2.1-14.93)	5.59(15.05)	5.58(2.46)	2.48(0.81)	p<0.005
Dabrafenib	Antineoplastic and immunomodulating agents	4	5.56(2.08-14.83)	5.55(14.91)	5.54(2.44)	2.47(0.8)	p<0.005
Trastuzumab	Antineoplastic and immunomodulating agents	4	5.17(1.94-13.8)	5.17(13.43)	5.16(2.27)	2.37(0.7)	p<0.005
Cyclosporine	Antineoplastic and immunomodulating agents	3	8.45(2.72-26.23)	8.44(19.64)	8.43(3.26)	3.07(1.41)	p<0.001
Imatinib	Antineoplastic and immunomodulating agents	3	8.06(2.6-25.03)	8.05(18.5)	8.04(3.12)	3.01(1.34)	p<0.001

Melphalan	Antineoplastic and immunomodulating agents	3	6.91(2.23-21.46)	6.91(15.13)	6.9(2.67)	2.79(1.12)	p<0.005
Siponimod	Antineoplastic and immunomodulating agents	3	6.22(2-19.31)	6.21(13.11)	6.21(2.4)	2.63(0.97)	p<0.005
Trametinib	Antineoplastic and immunomodulating agents	3	5.35(1.72-16.62)	5.35(10.59)	5.34(2.07)	2.42(0.75)	p<0.01
Doxycycline	Antiinfectives for systemic use	41	23.3(17.09-31.78)	23.24(851.41)	22.7(17.51)	4.5(2.84)	p<0.001
Minocycline	Antiinfectives for systemic use	14	33.57(19.82-56.86)	33.44(436.96)	33.17(21.34)	5.05(3.38)	p<0.001
Voriconazole	Antiinfectives for systemic use	7	8.27(3.93-17.38)	8.26(44.49)	8.23(4.42)	3.04(1.37)	p<0.001
Linezolid	Antiinfectives for systemic use	7	5.66(2.69-11.88)	5.65(26.7)	5.63(3.03)	2.49(0.83)	p<0.001
Tetracycline	Antiinfectives for systemic use	5	64.41(26.69-155.46)	63.94(308.89)	63.75(30.5)	5.99(4.32)	p<0.001
Metronidazole	Antiinfectives for systemic use	4	7.37(2.76-19.67)	7.37(21.96)	7.35(3.23)	2.88(1.21)	p<0.001
Valganciclovir	Antiinfectives for systemic use	3	28.94(9.31-89.99)	28.85(80.5)	28.8(11.14)	4.85(3.18)	p<0.001

Abbreviation: ROR, reporting odds ratio; PRR, proportional reported ratio;

BCPNN, Bayesian confidence propagation neural network;

MGPS, multi-item gamma poisson shrinker; CI, Confidence Interval. The P value represents the P value of the chi-square test in the PRR algorithm.